Millipore's novel Tyrosine Kinases with BioForm Technology helps in functional in vitro assembly of multiple protein targets. It provides a better biologically relevant environment for cell signalling research and discovery efforts. The product which is imported from its US base is available for India pharma and biotech sectors.
Tyrosine Kinases with BioForm Technology is developed by P A Technologies in Amherst, MA. Millipore acquired the company and has been able to capitalize the technology benefits by providing it to its customers.
"Conventional analysis of membrane protein signalling involves studying a single protein interacting with a single partner. Such analysis loses rich, two-dimensional information afforded by organization of proteins on the membrane surface, according to the company sources.
BioForm Technology enables the unique assembly of histidine-tagged proteins in an environment that mimics that created by a cell membrane. This template restores the organizing features of the membrane without the difficulties of membrane preparation and reconstruction procedures. The technology is adaptable to high throughput assay format and is applicable to many signaling systems.
Further the Tyrosine Kinases with BioForm Technology can be used in many key stages of drug discovery research, including early stage drug screening, signal transduction and regulation of enzymatic activity. Additionally, this new kinase assay platform may be used for functional in vitro assembly of multiple protein targets.
Established in 1954 as a high performance filtration products and services company, Millipore has grown into a partner for Life Science customers through R&D investment, organic growth and acquisitions. Companies acquired include Chemicon, Upstate, Linco and NovAseptic AB. The integrated company is now geared up to offer its customers innovative technologies and stronger application support to streamline progress. Its target profiling services, multiplex and traditional immunoassays and clinical lab contract services help its customers prioritize potential drug candidates, screen many biomarkers simultaneously, and conduct research and clinical studies.